2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets across the Asia-Pacific region.
Keep reading to see how the APAC pharmaceutical industry has fared in 2022, and how it is looking ahead to a new year as we leave the year of the tiger and enter the year of the rabbit (or the cat, depending on where you are)
Samsung Biologics to buy out Biogen’s stake in Samsung Bioepis
In January 2022, Samsung Biologics finalised an agreement to buy out Biogen’s stake in the Samsung Bioepis joint venture in January 2022. The deal will accelerate Samsung Bioepis’ biosimilar development capabilities and novel drug development performance. Samsung Biologics will continue to drive expansion in three core biopharmaceutical businesses – continued capacity enhancement, the establishment of growth opportunities in new business areas, and global expansion.
Chinese markets represents ‘single greatest generational opportunity’ for Pharma
The Chinese pharmaceutical market has been steadily changing from formerly generics-focused into an emphasis in innovation, driven in part by an aging population and government policies to meet these challenges. This article takes investigates the current biopharmaceutical economy in China, and key trends driving innovation.
Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwanese-based CDMO Bora Pharmaceuticals acquired niche generic drugs developer TWi Pharmaceuticals in an effort to expand their outsourced development and manufacturing services with increased capacity and manufacturing facilities. The acquisition marks a milestone in Bora’s history, enabling them to become the largest pharmaceutical group by volume in Taiwan.
The Korean biopharma market: Incentivizing innovation
Biopharmaceuticals in South Korea saw an unprecedented number of out-licensing deals and new drug approvals in the years leading up to 2022. However, the Korean biopharma market has yet to achieve commercial success of the same scale. We explore how the South Korean biopharmaceutical landscape and how drug innovation can be incentivised in a rapidly growing market in a framework dominated by out-licensing.
Thermo Fisher Scientific expands with state-of-the-art facility in China
A new state-of-the-art cGMP facility is now open in China as part of Thermo Fisher Scientific’s efforts to address the needs of companies and provide quicker access to therapies for patients in China and the APAC region. The facility offers integrated clinical and commercial drug type capabilities and process development through to sterile fill-finish. Thermo Fisher has announced plans to expand these capabilities to commercial packaging and labelling.
Lonza start commercial operations in newly expanded facility
Lonza Small Molecules have expanded their API manufacturing facility in Nansha, China to enable smoother transitions between small and large-scale manufacturing. The expansion includes manufacturing equipment to span the gap between early- and late-phase production.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance